Inotuzumabozogamicin is an effective treatment for CD22-positive acute undifferentiated leukemia: A case report

Pediatr Blood Cancer. 2021 May;68(5):e28976. doi: 10.1002/pbc.28976. Epub 2021 Feb 22.

Authors

Affiliations

¹ Department of Pediatrics, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
² Department of Pediatrics, Kitano Hospital, The Tazuke Kofukai, Medical Research Institute, Osaka, Japan.
³ Department of Human Health Sciences, Graduate School of Medicine, Kyoto University, Kyoto, Japan.

PMID: 33619873
DOI: 10.1002/pbc.28976

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Adolescent
Antineoplastic Agents, Immunological / therapeutic use*
Female
Humans
Inotuzumab Ozogamicin / therapeutic use*
Leukemia / drug therapy*
Sialic Acid Binding Ig-like Lectin 2 / antagonists & inhibitors*

Substances

Antineoplastic Agents, Immunological
CD22 protein, human
Sialic Acid Binding Ig-like Lectin 2
Inotuzumab Ozogamicin